As no pharmacological approach is available to specifically target the IR-A in cancer [29], we evaluated whether DDR1 targeting could be alternatively used as a strategy to inhibit IR-A-driven metabolic reprogramming in BC cells. This evidence concerns the gene DDR1 and breast cancer.